RAC.AX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 08:10):
Our systems believe the stock currently is overvalued by -0.53% compare to its pairs and should correct downwards.

Stats
Dagens volum	86 214
Gjennomsnittsvolum	178 746
Markedsverdi	309.95M
EPS	$-0.0346 ( Q2 \| 2023-12-31 )
Neste inntjeningsdato	( $0 ) 2024-07-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-26.00 (Sector) 0 (Industry) 0
ATR14	$0.00800 (0.44%)

ACW.AX 4.84%

ADO.AX 5.00%

AGH.AX 4.35%

ANP.AX -4.92%

ATH.AX 25.00%

AVE.AX -33.33%

BIT.AX 2.63%

BNO.AX -10.00%

BOT.AX -8.70%

CAN.AX 7.14%

CPH.AX 0.00%

CSL.AX -0.88%

CTE.AX 0.81%

CUV.AX -0.65%

CYP.AX 0.00%

DXB.AX 3.92%

ECS.AX 5.88%

EOF.AX -6.67%

GSS.AX 5.56%

IDT.AX -4.55%

IMC.AX -5.68%

IMM.AX 5.08%

IMU.AX -3.51%

IXC.AX 0.00%

KZA.AX 9.59%

LCT.AX 7.14%

LGP.AX 5.26%

MSB.AX 1.01%

MVP.AX -2.47%

MXC.AX 2.44%

NEU.AX -4.98%

NOX.AX 0.00%

NSB.AX 0.00%

OCC.AX 2.82%

OPT.AX -1.43%

OSL.AX 25.00%

PAA.AX 0.00%

PAB.AX 14.29%

PAR.AX 13.73%

PBP.AX 0.00%

PIQ.AX -1.14%

PTX.AX 5.26%

PXS.AX 3.70%

PYC.AX 0.00%

RAC.AX -0.27%

RCE.AX 5.26%

SPL.AX -3.16%

TLX.AX -3.00%

VBS.AX -1.30%

Korrelasjon (AI algo v.1.1b): Overvalued: -0.53% $1.820 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.01 (neutral)

Kort: 0.11 (neutral)

Signal:(46.309) Neutral

Race Oncology Ltd Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Race Oncology Ltd Korrelasjon - Valuta/Råvare

0.28
( neutral )

0.47
( neutral )

0.00
( neutral )

-0.08
( neutral )

Race Oncology Ltd Økonomi

Annual	2023
Omsetning:	$3.13M
Bruttogevinst:	$2.85M (91.03 %)
EPS:	$-0.0617

FY	2023
Omsetning:	$3.13M
Bruttogevinst:	$2.85M (91.03 %)
EPS:	$-0.0617

FY	2022
Omsetning:	$707 807
Bruttogevinst:	$426 611 (60.27 %)
EPS:	$-0.0731

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0794

Financial Reports:

No articles found.

Race Oncology Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Race Oncology Ltd

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.